TEL/AML1 Qualitative Test – Comprehensive Genetic Analysis for Leukemia Detection
Understanding the TEL/AML1 Qualitative Test
The TEL/AML1 Qualitative test represents a cutting-edge molecular diagnostic tool designed to detect specific genetic abnormalities associated with acute lymphoblastic leukemia (ALL). This sophisticated genetic analysis focuses on identifying the TEL-AML1 fusion gene, which results from a chromosomal translocation between chromosomes 12 and 21. This genetic rearrangement is one of the most common abnormalities found in childhood ALL, affecting approximately 25% of pediatric cases.
The importance of this test cannot be overstated in modern hematological diagnostics. By detecting the presence of the TEL-AML1 fusion gene, healthcare providers can confirm leukemia diagnosis, determine appropriate treatment protocols, and establish baseline measurements for monitoring treatment response. This test plays a vital role in personalized medicine approaches for leukemia patients.
What the TEL/AML1 Test Measures and Detects
The TEL/AML1 Qualitative test specifically targets and identifies the presence of the t(12;21)(p13;q22) chromosomal translocation. This genetic event creates a fusion between the TEL (ETV6) gene on chromosome 12 and the AML1 (RUNX1) gene on chromosome 21. The test utilizes advanced Real-Time PCR technology to:
- Detect the TEL-AML1 fusion transcript with high sensitivity
- Provide qualitative results indicating presence or absence of the fusion gene
- Offer reliable detection even at low levels of abnormal cells
- Support minimal residual disease monitoring when used in quantitative applications
Who Should Consider the TEL/AML1 Test?
This specialized genetic test is recommended for individuals presenting with symptoms or clinical findings suggestive of acute lymphoblastic leukemia. Consider scheduling this test if you or your child experience:
- Unexplained fatigue and weakness
- Frequent infections or prolonged illness
- Easy bruising or unusual bleeding
- Bone or joint pain
- Enlarged lymph nodes or spleen
- Pale skin or anemia symptoms
- Abnormal complete blood count results
- Family history of hematological malignancies
Clinical Indications Include:
- Initial diagnosis of suspected acute lymphoblastic leukemia
- Confirmation of ALL subtype classification
- Treatment planning and risk stratification
- Monitoring treatment response
- Detection of minimal residual disease
Benefits of Taking the TEL/AML1 Qualitative Test
Choosing the TEL/AML1 Qualitative test provides numerous advantages for patients and healthcare providers:
- Accurate Diagnosis: Provides definitive confirmation of TEL-AML1 positive ALL
- Treatment Guidance: Helps determine appropriate chemotherapy protocols
- Prognostic Information: TEL-AML1 positive ALL generally has favorable outcomes
- Early Detection: Enables prompt intervention and treatment initiation
- Personalized Care: Supports tailored treatment approaches based on genetic markers
- Monitoring Capability: Establishes baseline for future disease monitoring
Understanding Your Test Results
Interpreting TEL/AML1 Qualitative test results requires professional medical expertise. Here’s general guidance on what your results may indicate:
Positive Result:
- Confirms presence of TEL-AML1 fusion gene
- Indicates TEL-AML1 positive acute lymphoblastic leukemia
- Typically associated with favorable prognosis in pediatric cases
- May influence specific treatment decisions
Negative Result:
- Absence of detectable TEL-AML1 fusion gene
- Suggests alternative genetic abnormalities may be present
- Requires additional testing for comprehensive leukemia classification
- Does not rule out other forms of leukemia
Always discuss your specific results with your healthcare provider, who can provide personalized interpretation based on your complete clinical picture.
Test Details and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | TEL/AML1 Qualitative Test |
| Regular Price | $150 USD |
| Discount Price | $112 USD |
| Turnaround Time | 3-4 days |
| Sample Type | Bone marrow / Peripheral blood (Transport immediately) |
| Test Components | EDTA Vacutainer (2ml) |
| Testing Method | Real Time PCR |
Pre-Test Instructions and Requirements
The TEL/AML1 Qualitative test requires a Doctor’s prescription for most cases. Important pre-test considerations include:
- Prescription is mandatory for this genetic test
- Prescription requirements do not apply to surgery and pregnancy cases
- Prescription is not required for individuals planning to travel abroad
- Consult with your general physician for appropriate testing recommendations
- Ensure proper sample collection and immediate transport to laboratory
Nationwide Availability Across USA
We proudly serve patients across the United States with convenient testing locations in all major cities. Our network includes specialized collection centers in:
- New York City and surrounding areas
- Los Angeles and Southern California
- Chicago and Illinois region
- Houston and Texas metropolitan areas
- Miami and Florida locations
- Philadelphia and Pennsylvania centers
- And many more locations nationwide
Take Action Today – Book Your Test
Don’t wait to get the answers you need for proper leukemia diagnosis and treatment planning. Our experienced team is ready to assist you with:
- Professional sample collection
- Accurate genetic analysis
- Timely result delivery
- Comprehensive support throughout the testing process
Call or WhatsApp us today at +1(267) 388-9828 to schedule your TEL/AML1 Qualitative test. Our genetic specialists are available to answer your questions and help you understand the testing process. Take the first step toward accurate diagnosis and personalized treatment with our advanced genetic testing services.
